The Department of Energy has entered into an agreement with Serene to produce high specific activity (HSA) Sn-117m to be used in additional pre-clinical development through 2Q 2023. Thereafter, the HSA Sn-117m will be used throughout the completion of the FDA Phase 2 NIH-sponsored clinical trial of bone metastases.